Our in vivo studies performed with chronic administration of Juglone showed significant inhibition of Notch3-dependent leukemia growth through Notch3 downregulation, thus providing preclinical evidence of the efficacy of Notch3 targeting in T-ALL, which is becoming of great interest as a potential novel therapeutic approach15,59,60. The gene discussed is NOTCH3; the disease is leukemia.